Genmab A/S (GMAB)
After hours:
| Previous Close | 28.00 |
| Open | 28.51 |
| Bid | 27.97 x 100 |
| Ask | 28.01 x 100 |
| Day's Range | 27.90 - 28.53 |
| 52 Week Range | 26.32 - 42.72 |
| Volume | |
| Avg. Volume | 488,495 |
| Market Cap | 18.151B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | 23.34 |
| EPS (TTM) | 1.20 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.93 |
GlobeNewswireTransactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 20, 2024 to May 24, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement
Business WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
COPENHAGEN, Denmark, May 23, 2024--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, tisotumab vedotin, an antibody-drug conjugate (ADC), and acasunlimab (also known as GEN1046/BNT311), an investigational bispecific antibody, will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, May 31-June 2, 2024.
Business WireGenmab Completes Acquisition of ProfoundBio
COPENHAGEN, Denmark, May 21, 2024--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).
